New rules limit use of anemia drugs
Shares of Amgen slid on new government rules for reimbursing the biotech's blockbuster anemia drugs. The rules, though, are actually less restrictive than the proposed guidelines that were released for review earlier this year. The rules released today restrict the use of anemia drugs to prevent hemoglobin levels from declining.
- read the AP report on Amgen
Related Articles:
New Medicare cap on anemia drugs could hammer Amgen. Report
FDA panel votes for restrictions on anemia drugs. Report
Amgen stock slips as anemia drug concerns rise. Report
New study points to danger of anemia drug. Report
Major challenges loom for Amgen. Report
Be the first to comment
Comments
Post new comment
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
